CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of…


- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment-

Continued here:
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of...

Related Posts